Allogeneic or haploidentical HSCT for refractory or relapsed solid tumors in children: toward a neuroblastoma model.

Abstract:

:New concepts of allogeneic hematopoietic SCT (allo-HSCT) for neuroblastoma and other solid tumors do not rely on escalation of chemotherapy intensity and tumor load reduction but rather on a graft-vs-tumor effect. At this point, this is still an investigational and unusual application of allogeneic transplant, with 78 neuroblastoma patients reported to the European Group for Blood and Marrow Transplantation activity survey from 2002 to 2007 and less than 100 published cases. Two trends can be observed in the reviewed data: some teams have used allo-HSCT in children with refractory or progressive disease and significant tumor burden and other teams in children with CR, PR or minimal residual disease earlier in their disease process. Early studies of allo-HSCT in children with high-risk neuroblastoma suggest that this is a feasible approach that may improve outcome in this deadly disease. However, the proper timing for allo-HSCT during the disease course remains to be determined.

journal_name

Bone Marrow Transplant

authors

Kanold J,Paillard C,Tchirkov A,Merlin E,Marabelle A,Lutz P,Rousseau R,Baldomero H,Deméocq F

doi

10.1038/bmt.2008.279

subject

Has Abstract

pub_date

2008-10-01 00:00:00

pages

S25-30

eissn

0268-3369

issn

1476-5365

pii

bmt2008279

journal_volume

42 Suppl 2

pub_type

杂志文章,评审
  • Rapid and sustained hematopoietic reconstitution by peripheral blood stem cell infusion alone following high-dose chemotherapy.

    abstract::We utilized mobilized peripheral blood stem cells (PBSC) as sole support for hematologic reconstitution following high-dose chemotherapy in 52 patients with advanced solid tumors and lymphoma. PBSC were collected by large scale leukapheresis after mobilization with chemotherapy. Each apheresis product was analysed for...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Schwartzberg L,Birch R,Blanco R,Wittlin F,Muscato J,Tauer K,Hazelton B,West W

    更新日期:1993-05-01 00:00:00

  • Patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: trends in survival during the past two decades.

    abstract::It remains unclear how specific innovations in allogeneic hematopoietic cell transplantation (HCT) attained over the past decades have contributed to improvement in transplantation outcomes. To address this question, we conducted a registry-based study of adults with acute myeloid leukemia in first or second complete ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-018-0301-7

    authors: Yanada M,Masuko M,Mori J,Aoki J,Mizuno S,Fukuda T,Kakihana K,Ozawa Y,Ota S,Kanamori H,Mori T,Nakamae H,Eto T,Shiratori S,Maeda T,Iwato K,Ichinohe T,Kanda Y,Tanaka J,Atsuta Y,Yano S

    更新日期:2019-04-01 00:00:00

  • Successful program to prevent aspergillus infections in children undergoing marrow transplantation: use of nasal amphotericin.

    abstract::Aspergillus infections in the pediatric bone marrow transplant (BMT) patients are usually fatal. We began the use of a prophylactic nasal spray of amphotericin in 1990. This nasal spray was provided in addition to low-dose intravenous amphotericin. During the time of this study, the number of fatal cases of aspergillu...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1700618

    authors: Trigg ME,Morgan D,Burns TL,Kook H,Rumelhart SL,Holida MD,Giller RH

    更新日期:1997-01-01 00:00:00

  • ABO-incompatible bone marrow transplantation: a GITMO survey of current practice in Italy and comparison with the literature.

    abstract::ABO incompatibility is not considered a contraindication for allogeneic haematopoietic stem cell transplantation (HSCT) despite its association with several immunohaematological complications. At present, there is no general agreement concerning the best methods to reduce these problems. To survey current practice rel...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,多中心研究

    doi:10.1038/sj.bmt.1704579

    authors: Raimondi R,Soli M,Lamparelli T,Bacigalupo A,Arcese W,Belloni M,Rodeghiero F,Gruppo Italiano Trapianto di Midolla Osseo.

    更新日期:2004-08-01 00:00:00

  • Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted?

    abstract::The natural history of multiple myeloma (MM) was revolutionized by the introduction of haematopoietic stem cell transplantation to the treatment armamentarium of this disease. Defined subgroups of MM patients (such as the elderly or dialysis-dependent) have required an individualized approach in order to minimize the ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/sj.bmt.1705395

    authors: Bahlis NJ,Lazarus HM

    更新日期:2006-07-01 00:00:00

  • Evaluation of a monoclonal IgM antibody for purging of bone marrow for autologous transplantation.

    abstract::A monoclonal antibody of the IgM class, reacting with the CD9 (p24) antigen is described. The antibody (FMC27) is cytotoxic against cells of the common type of acute lymphoblastic leukaemia (c-ALL), giving killing at higher dilutions than an IgG antibody (FMC8) against the same antigen. FMC27 and FMC8 recognise differ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Zola H,Potter A,Neoh SH,Juttner CA,Haylock DN,Rice AM,Favaloro EJ,Kabral A,Bradstock KF

    更新日期:1987-02-01 00:00:00

  • Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization.

    abstract::Plerixafor is an inhibitor of CXCR-4 (CXC chemokine receptor-4)/SDF (stromal cell-derived factor)-1 binding used in combination with granulocyte colony-stimulating factor (G-CSF) for mobilization of autologous peripheral blood hematopoietic stem cells (HSCs). We developed a data-generated, cost-saving decision-making ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2010.78

    authors: Costa LJ,Alexander ET,Hogan KR,Schaub C,Fouts TV,Stuart RK

    更新日期:2011-01-01 00:00:00

  • Prognostic significance of microRNA-99a in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.

    abstract::Overexpression of microRNA-99a (miR-99a) have been associated with adverse prognosis in acute myeloid leukemia (AML). Nevertheless, whether it also predicts poor outcome in post-allogeneic hematopoietic stem cell transplantation (allo-HSCT) AML patients remains unclear. To further elucidate the prognostic value of miR...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-018-0146-0

    authors: Cheng Z,Zhou L,Hu K,Dai Y,Pang Y,Zhao H,Wu S,Qin T,Han Y,Hu N,Chen L,Wang C,Zhang Y,Wu D,Ke X,Shi J,Fu L

    更新日期:2018-09-01 00:00:00

  • Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers.

    abstract::Fms-like tyrosine kinase-3 ligand (Flt3L) uniquely binds the Flt3 (CD135) receptor expressed on hematopoietic stem cells (HSCs), early progenitor cells, immature thymocytes and steady-state dendritic cells (DCs) and induces their proliferation, differentiation, development and mobilization in the bone marrow, peripher...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2015.74

    authors: Anandasabapathy N,Breton G,Hurley A,Caskey M,Trumpfheller C,Sarma P,Pring J,Pack M,Buckley N,Matei I,Lyden D,Green J,Hawthorne T,Marsh HC,Yellin M,Davis T,Keler T,Schlesinger SJ

    更新日期:2015-07-01 00:00:00

  • Gene therapy for hematopoietic and immune disorders.

    abstract::Gene therapy is a novel approach under investigation for the treatment of genetic diseases, cancer and AIDS. Hematopoietic stem cells would be the target cell for correction of hemoglobinopathies, immune deficiencies and lysosomal storage diseases. Retroviral vectors derived from murine leukemia viruses have been used...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:

    authors: Kohn DB

    更新日期:1996-12-01 00:00:00

  • Intensive sequential dose dense chemotherapy with stem cell support as first-line treatment in advanced ovarian carcinoma: a phase II study.

    abstract::From August 1995 to December 1997, 15 patients with stage III-IV ovarian cancer were treated with outpatient intensive chemotherapy with G-CSF and stem cell support. The first cycle consisted of cyclophophamide IV 6 g/m(2); second, third, fourth and fifth paclitaxel 250 mg/m(2) and the sixth and seventh carboplatin AU...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.bmt.1703762

    authors: Viret F,Bertucci F,Genre D,Gravis G,Chabannon C,Conte M,Houvenaeghel G,Maraninchi D,Viens P

    更新日期:2002-12-01 00:00:00

  • Relationship between donor-recipient blood group incompatibility and serum bilirubin after allogeneic bone marrow transplantation from HLA-identical siblings.

    abstract::Data on 477 patients with hematologic malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings were analyzed for correlation between donor-recipient ABO blood group incompatibility and the development of elevated bilirubin levels (over 17 mmol/l) after transplantation. The median bili...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Mehta J,Powles R,Horton C,Milan S,Singhal S,Treleaven J

    更新日期:1995-06-01 00:00:00

  • Pulmonary toxicity associated with high dose chemotherapy in the treatment of solid tumors with autologous marrow transplant: an analysis of four chemotherapy regimens.

    abstract::We retrospectively reviewed the pulmonary toxicity of six high dose chemotherapy protocols using four chemotherapy regimens in the treatment of solid tumors. All protocols used either high dose cyclophosphamide or ifosfamide in combination with one to three additional chemotherapeutic agents. In each protocol autologo...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Seiden MV,Elias A,Ayash L,Hunt M,Eder JP,Schnipper LE,Frei E 3rd,Antman KH

    更新日期:1992-07-01 00:00:00

  • Ruxolitinib treatment for GvHD in patients with myelofibrosis.

    abstract::Jak1/2 inhibitor ruxolitinib is a promising agent for treating steroid-refractory GvHD after allogeneic hematopoietic stem cell transplantation (SCT) to produce quick and durable responses. However, optimal dose and tapering schedule of ruxolitinib remain to be determined. Discontinuation of ruxolitinib in myelofibros...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2016.256

    authors: Mori Y,Ikeda K,Inomata T,Yoshimoto G,Fujii N,Ago H,Teshima T

    更新日期:2016-12-01 00:00:00

  • Psychological distress of patients undergoing intensified conditioning with radioimmunotherapy prior to allogeneic stem cell transplantation.

    abstract::This is a pilot study comparing the emotional distress of patients receiving an intensified conditioning regimen (radioimmunotherapy=RIT) with patients receiving conventional conditioning for allogeneic stem cell transplantation. In total, 53 patients (18 received RIT) were given two questionnaires designed to measure...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704971

    authors: Grulke N,Bailer H,Kächele H,Bunjes D

    更新日期:2005-06-01 00:00:00

  • Comparison of allogeneic T cell-depleted peripheral blood stem cell and bone marrow transplantation: effect of stem cell source on short- and long-term outcome.

    abstract::We report the results of a retrospective single-center study comparing engraftment, acute and chronic GVHD, relapse and survival in patients with malignant hematological disorders transplanted with allogeneic peripheral blood stem cells (alloPBSCT, n = 40) or bone marrow cells (alloBMT, n = 42). All transplants were T...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1703024

    authors: Barge RM,Brouwer RE,Beersma MF,Starrenburg CW,Zwinderman AH,Hale G,Waldmann H,den Ottolander GJ,Falkenburg JH,Willemze R,Fibbe WE

    更新日期:2001-05-01 00:00:00

  • Early iron reduction programme for thalassaemia patients after bone marrow transplantation.

    abstract::Thirty thalassaemia patients received iron reduction starting at around 3 months post transplant. Sixteen received desferrioxamine and nine had phlebotomy, five patients had desferrioxamine followed by phlebotomy. The desferrioxamine group had higher serum ferritin levels at the start of iron reduction as compared to ...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.bmt.1702212

    authors: Li CK,Lai DH,Shing MM,Chik KW,Lee V,Yuen PM

    更新日期:2000-03-01 00:00:00

  • Evaluation of pretransplant influenza vaccination in hematopoietic SCT: a randomized prospective study.

    abstract::Pretransplant influenza vaccination of the donor or allogeneic hematopoietic SCT (HSCT) candidate was evaluated in a randomized study. One hundred and twenty-two HSCT recipients and their donors were assigned to three randomization groups: no pretransplant vaccination (n=38), donor pretransplant vaccination (n=44) or ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1038/bmt.2015.47

    authors: Ambati A,Boas LS,Ljungman P,Testa L,de Oliveira JF,Aoun M,Colturato V,Maeurer M,Machado CM

    更新日期:2015-06-01 00:00:00

  • Early cyclosporine taper in high-risk sibling allogeneic bone marrow transplants.

    abstract::Graft-versus-tumour reactions as a form of adoptive immunotherapy may help prevent the recurrence of haematological malignancy following allogeneic BMT. We hypothesised that such reactions may be maximised by shortening the duration of post-transplant immunosuppression by a rapid taper of cyclosporine (CYA). CYA dose ...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.bmt.1700961

    authors: Abraham R,Szer J,Bardy P,Grigg A

    更新日期:1997-11-01 00:00:00

  • Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath).

    abstract::Infectious complications due to adenovirus are of increasing concern after allogeneic stem cell transplantation. Over the past 4 years, we have modified our conditioning regimens to use alemtuzumab in preference to anti-thymocyte globulin (ATG) for pediatric patients receiving stem cell transplants from alternate dono...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1705164

    authors: Myers GD,Krance RA,Weiss H,Kuehnle I,Demmler G,Heslop HE,Bollard CM

    更新日期:2005-12-01 00:00:00

  • Immunologic recovery after autologous blood stem cell transplantation in patients with AL-amyloidosis.

    abstract::We prospectively studied absolute lymphocyte (ALC) and monocyte counts (AMC), lymphocyte subsets and proliferative in vitro responses to mitogen and antigen in 12 patients with AL-amyloidosis (AL) undergoing autologous blood stem cell transplantation (SCT) with high-dose i.v. melphalan. Myeloid and lymphoid recovery (...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1703298

    authors: Akpek G,Lenz G,Lee SM,Sanchorawala V,Wright DG,Colarusso T,Waraska K,Lerner A,Vosburgh E,Skinner M,Comenzo RL

    更新日期:2001-12-01 00:00:00

  • Risk of relapse in patients receiving azithromycin after allogeneic HSCT.

    abstract::Following publication of the ALLOZITHRO trial, the FDA released a safety announcement warning that azithromycin should not be given long-term to prevent BOS in patients with a blood or lymph cancer who have undergone allogeneic HSCT. Our site typically initiated azithromycin when patients were diagnosed with BOS post-...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-01095-8

    authors: Kutzke JL,Merten JA,Taraba JL,Mara KC,Shah MV,Hashmi SK,Patnaik MM,Litzow MR,Hogan WJ,Alkhateeb HB

    更新日期:2020-10-31 00:00:00

  • High dose carboplatin/VP-16 plus ifosfamide with autologous bone marrow support in the treatment of refractory germ cell tumors.

    abstract::We report seven patients with germ cell tumors which either recurred following a minimum of two regimens of platinum-based chemotherapy or were refractory to cisplatin. The patients were treated with one or two courses of high dose carboplatin (CBDCA) and etoposide (VP-16) plus ifosfamide (IFX) with mesna uroprotectio...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:

    authors: Broun ER,Nichols CR,Tricot G,Loehrer PJ,Williams SD,Einhorn LH

    更新日期:1991-01-01 00:00:00

  • High interleukin-10 serum levels are associated with fatal outcome in patients after bone marrow transplantation.

    abstract::IL-10 plays an important role in the control of immune reactions during systemic infection. Here, IL-10 serum levels were investigated in patients after BMT. The IL-10 levels correlated with the clinical course of the patients and with serum levels of C-reactive protein (CRP) and neopterin (NP). A total of 26 patients...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1700902

    authors: Hempel L,Körholz D,Nussbaum P,Bönig H,Burdach S,Zintl F

    更新日期:1997-09-01 00:00:00

  • Kaposi's sarcoma following allogeneic bone marrow transplantation.

    abstract::Localised Kaposi's sarcoma (KS) was diagnosed 240 days after allogeneic bone marrow transplantation (BMT) in a severely immunosuppressed HIV negative patient with genetic predisposition. The tumour was of host origin, based on PCR amplification of DNA minisatellites. Treatment with radiotherapy prompted almost complet...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Helg C,Adatto M,Salomon D,Roux E,Miralbell R,Chapuis B,Saurat JH

    更新日期:1994-12-01 00:00:00

  • Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT.

    abstract::Detectable measurable residual disease (MRD) is a key prognostic factor in both acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) patients. Thus, we conducted a survey in EBMT transplant centers focusing on pre- and post-allo-HCT MRD. One hundred and six centers from 29 countries responded. One hundr...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-01005-y

    authors: Nagler A,Baron F,Labopin M,Polge E,Esteve J,Bazarbachi A,Brissot E,Bug G,Ciceri F,Giebel S,Gilleece MH,Gorin NC,Lanza F,Peric Z,Ruggeri A,Sanz J,Savani BN,Schmid C,Shouval R,Spyridonidis A,Versluis J,Mohty M

    更新日期:2021-01-01 00:00:00

  • Hematopoietic stem cell transplantation (HSCT) for Langerhans cell histiocytosis (LCH) in Japan.

    abstract::There exists limited information about the usefulness of hemopoietic stem cell transplantation (HSCT) for the treatment of patients with refractory Langerhans cell histiocytosis (LCH). We report here four Japanese pediatric patients with multisystem LCH disease who underwent HSCT between 1994 and 1997. Two of the four...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702001

    authors: Kinugawa N,Imashuku S,Hirota Y,Yamada K,Yamamoto A,Akazai A,Oda M,Miura N,Kakuta H,Sato T,Endo M,Takano T

    更新日期:1999-10-01 00:00:00

  • Autologous stem cell transplantation for clinically aggressive non-Hodgkin's lymphoma: the role of preparative regimens.

    abstract::We investigated the impact of the most commonly used preparative regimens on the outcome of 395 patients with diffuse large cell lymphoma (DLCL), consecutively reported to the registry of the Spanish GEL/TAMO. Among them, 139 (35%) were autografted in 1st CR, 86 (22%) in 2nd/3rd CR, 124 (31%) had chemosensitive diseas...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,多中心研究

    doi:10.1038/sj.bmt.1702795

    authors: Salar A,Sierra J,Gandarillas M,Caballero MD,Marín J,Lahuerta JJ,García-Conde J,Arranz R,León A,Zuazu J,García-Laraña J,López-Guillermo A,Sanz MA,Grañena A,García JC,Conde E,GEL\/TAMO Spanish Cooperative Group.

    更新日期:2001-02-01 00:00:00

  • Transplantation with peripheral blood stem cells, manipulated or unmanipulated, for the treatment of high-risk childhood leukemia.

    abstract::Collection of peripheral blood stem cells (PBSC) does not require anesthesia or multiple marrow aspirations, and hence, is far less invasive than bone marrow collection. Most importantly, PBSC can be collected from the body's entire pool of HSC to provide more stem cells than marrow aspiration performed at localized i...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:

    authors: Takaue Y,Kawano Y,Watanabe T,Watanabe A

    更新日期:1998-12-01 00:00:00

  • Targeting mycophenolate mofetil for graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation.

    abstract::As low trough levels of mycophenolic acid (MPA) have been measured in recipients of allo-SCTs, we performed a pilot study targeting mycophenolate mofetil (MMF) doses according to the MPA area under the concentration (AUC) levels. Twenty-nine patients were transplanted from matched sibling (n=7) and unrelated donors (n...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2008.85

    authors: Haentzschel I,Freiberg-Richter J,Platzbecker U,Kiani A,Schetelig J,Illmer T,Ehninger G,Schleyer E,Bornhäuser M

    更新日期:2008-07-01 00:00:00